Artificial Intelligence: Daphne Koller Raises $143M For Insitro, Her AI-Bio Startup
Insitro is a startup that combines cutting-edge biopharma with machine learning.
Daphne Koller is the face of Insitro. Venture capitalists swear by her and have just handed her $143 million to be used by Insitro for boosting its capabilities to develop new drugs.
The startup has therefore raised $243 million in total to date. That’s a not inconsequential sum considering it has only been in existence for two years. But then Koller inspires trust: she is a co-founder of online education platform Coursera, a computer science professor at Stanford, and a MacArthur Fellowship recipient. (Forbes)
Andreessen Horowitz led the $143 million funding round. New investors who participated included T. Rowe Price Associate, BlackRock, Casdin Capital, and CPP Investments. Current investors including ARCH Venture Partners, GV, and Third Rock Ventures also invested.
VCs back Koller’s exceptional attributes
Vijay Pande, a general partner at Andreessen Horowitz and a member of Insitro’s board, says Koller is “a pioneer at the intersection of machine learning and biopharma,” and “exactly the type of entrepreneur we are looking for.”
“She’s just exceptional,” says Robert Nelsen of ARCH Venture Partners.
What Insitro does
In its goal to find new drugs that focus on liver diseases and disorders of the central nervous systems, Insitro uses a rare combination of biology and machine learning.
It creates “test-tube experiments” that replicate cells in an environment outside the human body. From these, Insitro tries to predict what drug developers would see in a live but diseased human being. The researchers use machine learning to pinpoint differences between healthy cells and sick cells. The results from these studies could help in the development of new drug targets.
The start-up is currently working on a drug for liver disease for which it has a tie-up with Gilead – the three-year deal envisaged a $ 15 million upfront payment and potential for payments of $ 1 billion down the line. Insitro gets access to data from Gilead’s clinical trials which it can use to train its machine learning platform.
Insitro is also working on its own set of central nervous system disorders such as bipolar.
Latest Alternative Investment News
Funds and accounts advised by T. Rowe Price Associates, Inc. led an investment round worth $2.5 billion in electric vehicle maker Rivian. Participants in this investment round include Soros Fund…
PE Partnership Terms – Best Practices Callan, an institutional investment consulting firm, released its Private Equity Fees and Terms Study to serve as a reference for institutional investors. This study…
Clear, a blockchain startup founded in 2018, specializes in removing complex frictions in B2B trade. One such pain point is the contractual settlement and reconciliation for roaming agreements between telecom…
Alternative Investment: Vanguard Launches Its First ESG-focused Fixed Income Product For U.S. Investors
Vanguard filed a preliminary prospectus for a corporate bond ETF that will offer U.S. investors investment-grade corporate bonds with additional exposure to environmental, social, and governance (ESG) criteria. Vanguard has…